News · Category

Pharma & Biotech

Drug developers, biotech and life sciences.

Pharma & Biotech

Merck secures first approval for an oral PCSK9 inhibitor, reshaping the cholesterol market

Lipfendra clears the FDA as the first oral entrant in a class previously limited to injectables, with a NICE appraisal pending.

PremiumS. Adeyemi·5 min read·27 Sept 2026, 02:30

Pharma & Biotech

Lilly agrees $2.8bn AtaiBeckley acquisition in neuropsychiatry push

The transaction gives Lilly a late-stage psychedelic-derived asset portfolio.

S. Adeyemi·5 min read·22 Sept 2026, 08:30

Pharma & Biotech

AstraZeneca Advances Oral Obesity Drug into Phase 3, Signalling Intensified Competition

AstraZeneca has announced its oral GLP-1 receptor agonist, AZN-789, has entered Phase 3 trials, intensifying the race for market share in the burgeoning obesity treatment landscape. The move positions the Anglo-Swedish pharmaceutical giant as a significant challenger to established players.

Oruaro Onibere·7 min read·27 Aug 2026, 09:00

Showing 1–3 of 3 stories